Geneva, July 7 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT1041260072) titled 'A Phase II Randomized Study Comparing PARP Inhibitor Maintenance Regimens in High-Risk Advanced Ovarian Cancer' on June 24.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
Primary Sponsor: Kajiyama Hiroaki
Condition:
Ovarian cancer
D010051
Intervention:
Patients with advanced ovarian cancer who have undergone neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS), who achieved optimal debulking with a maximum residual tumor diameter of 1 cm or less and were confirmed to have homologou...